CLS signs supplier agreement with yet another hospital in the US
Clinical Laserthermia Systems (CLS) (publ) has, through its subsidiary CLS Americas Inc., signed a supplier agreement with yet another hospital in the US. The agreement was signed with the same leading American hospital that earlier this year purchased the TRANBERG® |Thermo Therapy System as well as single use accessories for MR-guided laser ablation. The agreement means that CLS is an approved supplier to the hospital, which is a prerequisite for the company when delivering equipment. The hospital has so far used the previously delivered TRANBERG-system and single use products for treatment of two patients.
- The two patients have received ablation treatment for another indication than cancer, and CLS’ products have performed well in this context. The fact that the hospital sees an opportunity for a broader use of our products is of course very positive. At this point we can unfortunately not share any detailed information, since the treating physician would like to have the possibility to publish results from his ongoing work, said Dan Mogren, Chief Commercial Officer at CLS.
CLS has for some time collaborated with the hospital’s department of interventional radiology, which has extensive activities in the area of image guided minimal invasive treatment of tumor diseases. The objective of the collaboration is to evaluate and further develop CLS’ immunostimulating treatment, imILT® as well as MR-guided laser ablation.
This information is such that Clinical Laserthermia Systems AB (publ) is required to publish pursuant to the EE Market Abuse Directive. The contact person arranged for the release of this information on 20 October 2017, at 03:00 PM.
Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)702 – 90 33 00 E-mail: lee@clinicallaser.se
Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG®|Thermal Therapy System and specially designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immunostimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and have subsidiaries in Berlin, Germany and Boston, MA,USA, is listed Nasdaq First North under the ticker CLS B. Certified Adviser is Västra Hamnen Corporate Finance. Further information is available on the company’s website: www.clinicallaser.se